Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.
2.

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M.

J Infect Dis. 2004 Mar 1;189(5):837-46. Epub 2004 Feb 10.

PMID:
14976601
3.

Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.

Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier ER, Hellmann NS, Richman DD.

Antivir Ther. 2003 Dec;8(6):489-506. Review.

PMID:
14760883
4.

Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ.

Antimicrob Agents Chemother. 2004 Feb;48(2):437-43.

5.

Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing.

Gonzales MJ, Johnson E, Dupnik KM, Imamichi T, Shafer RW.

J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):398-402.

7.

Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ.

J Infect Dis. 2003 Oct 1;188(7):992-1000. Epub 2003 Sep 16.

PMID:
14513419
8.

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

Røge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J, Gerstoft J.

Antivir Ther. 2003 Apr;8(2):173-82.

PMID:
12741630
9.

Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.

Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ, Shafer RW.

AIDS. 2003 Apr 11;17(6):791-9.

10.

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.

Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):121-7.

PMID:
12394789
11.

Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Shafer RW.

Clin Microbiol Rev. 2002 Apr;15(2):247-77. Review.

Supplemental Content

Support Center